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Abstract
Background: Bronchiolitis obliterans organizing pneumonia (BOOP) is a type of diffuse interstitial lung disease
characterized by the pathology of fibroblastic plugs in the lumens of the respiratory bronchioles, alveolar ducts, and
alveoli. The occurrence of BOOP in human immunodeficiency virus (HIV)-infected patients has rarely been
described, and there have been no clinical case reports in Korea.
Case presentation: A 24-year-old female who had been diagnosed with HIV ten years prior was admitted due to a
1-year history of cough and sputum production and a 3-day history of fever. She had poor adherence to anti-retroviral
therapy (ART) due to gastrointestinal troubles. At the time of admission, her CD4 T-cell count was 5 cells/mm3. A high
resolution computed tomography (CT) scan showed tiny centrilobular nodules with a tree-in-bud pattern in both
lungs. Bacterial culture, Pneumocystis jirovecii polymerase chain reaction (PCR), Aspergillus galactomannan antigen (Ag)
assay, and respiratory virus PCR were negative. Rapid chest x-ray improvement was seen after a 7-day treatment with
anti-tuberculosis medication, ceftriaxone, and clarithromycin. Miliary tuberculosis seemed unlikely considering the
rapid radiologic improvement and negative tuberculosis PCR results. Due to the unknown etiology, we performed
video-assisted thoracoscopic surgery (VATS) to determine the cause of the diffuse lung infiltration. Pathologic findings
were consistent with BOOP, while tissue acid-fast bacilli (AFB) stain and tuberculosis PCR results were negative.
Tuberculosis medication and intravenous ceftriaxone were discontinued, while treatment with clarithromycin
monotherapy was sustained. Five months after discharge, the patient was asymptomatic with a normal chest x-ray and
as her adherence to ART improved, her CD4 T-cell count rose to 181 cells/mm3. Clarithromycin was discontinued at
that time and the patient is currently receiving regular outpatient follow-up.
Conclusion: This case suggests that macrolides are a potential treatment option in HIV-infected patients with mild
BOOP. In cases that are otherwise unexplained or unresponsive to treatment, BOOP should be taken into consideration
and surgical biopsy performed to confirm a diagnosis of BOOP.
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Background
Bronchiolitis obliterans organizing pneumonia (BOOP)
is a type of diffuse interstitial lung disease characterized
by the pathology of fibroblastic plugs in the lumens of
the respiratory bronchioles, alveolar ducts, and alveoli
[1]. Various lung diseases have been reported in patients
infected with human immunodeficiency virus (HIV), but
there are few reports of the occurrence of BOOP in HIV
patients and prior to this study, there was no clinical
case report in Korea [2]. Here, we describe a unique case
of BOOP in a HIV-infected patient diagnosed by surgical
lung biopsy and successfully treated with clarithromycin.
Case presentation
A 24-year-old female was admitted for a 1-year history
of cough and sputum production and a 3-day history of
fever. She had been diagnosed with HIV infection 10 years
prior, and prescribed anti-retroviral therapy medications
(ART; Rilpivirine 25 mg once/day, Lamivudine 300 mg/
Abacavir 600 mg once/day, Raltegravir 400 mg twice/day),
but had poor adherence due to gastrointestinal troubles.
Her CD4 T-cell count 3 months before admission was 15
cells/mm3, and her viral load had not been suppressed for
several years. On admission, her temperature was 37 °C,
respiratory rate was 20 breaths per minute, pulse was 108
beats per minute, and blood pressure was 102/74 mmHg.
Auscultation of her lungs revealed coarse breath sounds
with crackles in the bilateral lower lung fields. A complete
blood cell count and blood chemistry on admission re-
vealed a white blood cell count of 4,240/mm3 (neutro-
phils, 88.5 %; lymphocytes, 6.1 %), hemoglobin level of
13.0 g/dL, and platelet count of 66,000/mm3. Arterial
blood gas analysis measured while breathing room air
showed an arterial oxygen partial pressure (PaO2) of
74.2 mmHg, arterial carbon dioxide partial pressure
(PaCO2) of 37.4 mmHg, and oxygen (O2) saturation of
95.3 %. Quantitative real-time polymerase chain reac-
tion showed a HIV viral load of 851,000 copies/mL, and
the patient’s CD4 T cell count was 5 cells/mm3. Chest
radiography on admission revealed diffuse bilateral reticu-
lar infiltrates in bilateral lung fields (Fig. 1). A high reso-
lution computed tomography (CT) scan showed tiny
centrilobular nodules with a tree-in-bud pattern in both
lungs (Fig. 2). To evaluate the possibility of community-
acquired bacterial pneumonia, a urine Streptococcus pneu-
moniae antigen (Ag) test, sputum Legionella pneumophila
polymerase chain reaction (PCR) test, and sputum and
blood cultures were done. All results were negative. Viral
pneumonia was also considered and PCR tests were per-
formed to detect adenovirus, respiratory syncytial virus,
influenza viruses A and B, coronavirus, and parainfluenza
virus, but all results were negative. Pneumocystis jirovecii
PCR, Aspergillus galactomannan Ag assay, and crypto-
coccal Ag test results were also negative. We considered
cytomegalovirus (CMV) pneumonitis, and CMV quantita-
tive PCR revealed 13,650 copies/mL. However, the patient’s
clinical symptoms and chest x-ray improved without any
treatment for CMV. Miliary tuberculosis was initially sus-
pected, and anti-retroviral agents (elvitegravir 150 mg, cobi-
cistat 288.5 mg, emtricitabine 200 mg, tenofovir 300 mg)
and anti-tuberculosis medication (isoniazid 300 mg once/
day, ethambutol 1200 mg once/day, pyrazinamide 1500 mg
once/day, and rifabutin 300 mg 3 times/week) were admin-
istered. At the same time, ceftriaxone 2 g once daily and
clarithromycin 500 mg twice daily were administered, as
the clinicians were unable to rule out concurrent bacterial
Fig. 1 Chest radiography on admission. Diffuse bilateral reticular
infiltrates in the bilateral lung fields were present
Fig. 2 High resolution computed tomography (CT) scan showing
tiny centrilobular nodules with a tree-in-bud pattern in both lungs
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infection. On the 7th day of hospitalization, the patient’s
chest x-ray showed rapid improvement. The patient did
not present with any symptoms suggestive of inflammatory
connective tissue diseases, such as arthralgia or dry eyes,
and had no exposure history to irradiation or fumes, which
are known to cause inflammatory injury to the lungs.
Contrary to the clinicians’ initial suspicion of miliary
tuberculosis, results of an interferon γ releasing assay
(IGRA), sputum acid-fast bacilli (AFB) stain, and tuber-
culosis PCR were negative. Overall, the etiology remained
unknown, so on the 8th day of admission, we performed
video-assisted thoracoscopic surgery (VATS) to determine
the cause of the patient’s diffuse lung infiltration. Micro-
scopic examination showed patchy fibroblastic plugs in
the bronchioles and alveolar ducts, consistent with BOOP,
while tissue AFB stain and tuberculosis PCR tests were
negative (Fig. 3). Anti-tuberculosis medications and ceftri-
axone were discontinued, and oral clarithromycin 500 mg
twice a day was continued. Follow-up chest radiography
and clinical symptoms of cough and sputum production
improved prior to discharge (Fig. 4). Five months after dis-
charge, the patient was asymptomatic with a normal chest
x-ray. Furthermore, as the patient’s adherence to ART
improved, her CD4 T-cell count rose to 181 cells/mm3.
Clarithromycin was discontinued at that time and the
patient is currently receiving regular outpatient follow-up.
Discussion
BOOP is a diffuse interstitial lung disease that affects the
small airways [1]. The precise incidence and prevalence of
BOOP is unknown, though a study performed in Italy con-
firmed 78 cases of biopsy-proven BOOP in a 7 year period
in a single center [3]. Clinical features of this disease in-
clude fever, mild dyspnea, and cough, similar to flu-like
symptoms [4]. The pathogenesis of BOOP is thought to be
due to epithelial injury followed by formation of fibrinoid
inflammatory cell clusters and consequently intra-alveolar
fibrosis [4]. The pathologic hallmark of BOOP is the pres-
ence of fibroblastic plugs in the lumens of the respiratory
bronchioles, alveolar ducts, and alveoli. [5]. Due to these
characteristic pathologic findings, biopsy for diagnosis of
BOOP is essential [4, 5]. Transbronchial lung biopsy may
be performed, but video-assisted thoracoscopic lung bi-
opsy is the preferred technique because it is more likely to
provide an adequate amount of tissue [4, 5]. Because
BOOP occurs as a result of an inflammatory response to
lung injury, a good treatment response is seen with broad-
spectrum anti-inflammatory agents, such as corticoste-
roids and immune-modulatory macrolides [6]. A few case
reports have described treatment of BOOP in non-HIV-
infected patients with macrolide antibiotics, but there have
been no studies of their use in HIV-positive patients [7].
High dose oral glucocorticoid therapy of 0.75-1 mg/kg per
day is suggested for initial treatment of patients with se-
vere symptoms [1]. There are no established guidelines
regarding duration of treatment, though a total of 1 year is
often recommended due to frequent relapses in cases in
which therapy was discontinued earlier [4]. Immune-
modulatory macrolides treat mild diseases such as BOOP
by inhibiting pro-inflammatory cytokine production [8, 9].
There is a reasonable chance that BOOP in a HIV-
infected patient may be underdiagnosed, considering
that areas of high HIV prevalence are usually resource-
limited and lung biopsies are not readily performed in
these places. Until now, concurrent BOOP and HIV
Fig. 3 Microscopic examination of the lung tissue at x100 magnification
after H&E staining. Patchy fibroblastic plugs in the bronchioles and
alveolar ducts were observed, consistent with BOOP
Fig. 4 Chest X-ray on the 15th day of admission. Note resolution of
the diffuse bilateral reticular infiltrates
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infection has been reported in only 11 patients. Diagno-
ses were made via transbronchial or thoracoscopic bi-
opsy, and a rapid treatment response was seen with the
use of corticosteroids. However, in one case, fatal pul-
monary aspergillosis occurred, and CMV retinitis and
esophagitis occurred in two cases. These complications
imply that prolonged use of corticosteroids in HIV-
infected BOOP patients may result in fatal clinical out-
comes secondary to their immunocompromised state
[2]. Both HIV and non-HIV infected patients respond
well to glucocorticoid therapy; however, prolonged use
of steroids in patients with concomitant HIV and BOOP
can increase the risk of opportunistic infections [10]. While
there are many known side-effects associated with long-
term use of corticosteroids, macrolides have been shown
to be effective and relatively safe to use on a long-term
basis [6]. In previous case reports (Allen et al., Liote et al.,
Laguna Del Estal et al. and Santio et al.), HIV infected pa-
tients with BOOP presented with a low CD4 cell count or
a low CD4/CD8 ratio, suggesting that severe immune defi-
ciency may be needed for BOOP to develop in this sce-
nario [11]. When treating HIV-infected patients who have
low immune status, physicians should consider a diagnosis
of BOOP in patients unresponsive to treatment for more
common conditions, such as Pneumocystis jirovecii pneu-
monia, or when the etiology is unknown [12].
The limitations of this case report are as follows. The
patient’s CD4 T-cell count improved significantly (from
5 to 181 cells/mm3) from the time of diagnosis of BOOP
until the end of macrolide treatment. This improvement
in immune status may have provided protection from
other opportunistic infections. Empirical treatment with
ceftriaxone may have improved the clinical course, and
there is also the chance that the BOOP resolved spon-
taneously. Our evaluation of the patient’s response to
clarithromycin treatment may not have been accurate
for the above reasons.
Conclusions
In summary, this case suggests that macrolides are a po-
tential treatment option in HIV-infected patients with
mild BOOP. In cases that are otherwise unexplained or
unresponsive to treatment, BOOP should be taken into
consideration and surgical biopsy performed to confirm a
diagnosis of BOOP.
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